PD-1 Antibody (SHR-1210) Plus Capecitabine in Patients with Intrahepatic Cholangiocarcinoma After Surgery

Phase 2Active Not RecruitingNCT04295317

Shanghai Zhongshan Hospital65 enrolled

Overview

SHR-1210 is a humanized anti-PD-1 Immunoglobulin G4 (IgG4) monoclonal antibody. This is an open- label,single center,non-randomized ,single arm exploratory study . This clinical study is an investigator-initiated clinical trial(IIT) .The objective of this study is to evaluate the efficacy and safety of therapy with anti-PD-1 antibody SHR-1210 plus Capecitabine in patients with Intrahepatic Cholangiocarcinoma After Surgery.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Intrahepatic Cholangiocarcinoma

Interventions

PD-1 blocking antibody SHR-1210DRUG

PD1 antibody SHR-1210 D1 200 mg every three weeks; Three weeks is a course of treatment with a total of 8 courses, or the patient has tumor recurrence or metastasis (requires imaging to determine tumor recurrence or metastasis)

CapecitabineDRUG

Capecitabine 2500mg / m2/ d, 2 times/d for 2 weeks, followed by 1 week of stopping ,Three weeks is a course of treatment with a total of 8 courses, or the patient has tumor recurrence or metastasis (requires imaging to determine tumor recurrence or metastasis)

Eligibility

Sex: ALLMin age: 18 YearsMax age: 75 Years

Medical Language ↔ Plain English

Inclusion Criteria: * age:18-75 years, male or femal; * Intrahepatic Cholangiocarcinoma confirmed by histopathology, R0 resection was classified as Stage IB, Stage II, Stage IIIA, Stage IIIB, or Stage IA with histolgoic grade G3 according to AJCC TNM (8th edition, 2017); * No extrahepatic metastases; * preoperative assessment of Child-Pugh A，ECOG Performance Status 0-1; * Subjects with chronic HBV infection must have HBV-DNA \<500 IU / ml; * Functional indicators of vital organs meet the following requirements: Neutrophils ≥1.5\*109/L; platelets≥50\*109/L; hemoglobin≥90g/l; Alanine aminotransferase （ALT） and Aspartate aminotransferase （AST） ≤ 2.5 times ULN,total bilirubin≤1.5 ULN; International standardized ratio (INR) ≤2.3ULN,creatinine ≤1.5 ULN; * No tumor recurrence or metastasis was observed. Exclusion Criteria: * Pathological diagnosis of hepatocellular carcinoma, mixed liver cancer, hilar bile duct cancer; * No anti-tumor treatment for Intrahepatic Cholangiocarcinoma, including chemotherapy and topical treatment, before surgery; * Known history of hypersensitivity to macromolecular protein preparation or any components of the SHR- 1210 formulation; * Tumors are not completely removed, or postoperative pathology suggests non-Intrahepatic Cholangiocarcinoma or other malignant components; * Subjects with any active autoimmune disease or history of autoimmune disease; * Uncontrolled clinically significant heart disease, including but not limited to the following: (1) \> NYHA II congestive heart failure; (2) unstable angina, (3) myocardial infarction within the past 1 year; (4) clinically significant supraventricular arrhythmia or ventricular arrhythmia requirement for treatment or intervention; * Active infection or an unexplained fever \> 38.5°C during screening or before the first scheduled day of dosing (subjects with tumor fever may be enrolled at the discretion of the investigator); * Received a live vaccine within 4 weeks of the first dose of study medication; * .Pregnancy or breast feeding; * Decision of unsuitableness by principal investigator or physician-in- charge.

Locations (1)

180 Fenglin Road

Shanghai, Shanghai Municipality, China

Outcomes

Primary Outcomes

recurrence-free survival

From the date of enrollment to the date of diagnosis of tumor recurrence

Time frame: 24 months

Secondary Outcomes

overall survival

From the date of enrollment to the date of death

Time frame: 24 months

the potential side effects

Time frame: 24 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.